← All trials
NCT06905522
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 15, 2025
- Primary completion
- Jan 31, 2029
- Completion date
- Dec 31, 2029
- First posted
- Apr 1, 2025
- Last posted
- Apr 1, 2025
- Enrollment
- 610
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Shenzhen Third People's HospitalLead sponsor
- Shenzhen Third People's HospitalSponsor investigator
- Shenyang Tenth People's HospitalCollaborator
- Zhejiang UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.